Literature DB >> 9114056

Ras-dependent pathways induce obstructive hypertrophy in echo-selected transgenic mice.

K R Gottshall1, J J Hunter, N Tanaka, N Dalton, K D Becker, J Ross, K R Chien.   

Abstract

To overcome the genetic and interindividual variability frequently noted in complex phenotypes, we used echocardiographic selection to develop a substrain of myosin light chain (MLC)-Ras (RAS) transgenic mice with an enhanced ventricular hypertrophic phenotype. These echo-selected mice were then compared with wild-type (WT) animals and a pressure overload hypertrophy model (transverse aortic constriction; TAC). Echocardiography demonstrated increased wall thickness in RAS compared with the other groups. We developed novel miniaturized physiological technology to quantitatively identify in vivo intraventricular gradients; increased systolic Doppler velocity was seen in the left ventricle (LV) in 69% of RAS vs. none of WT or TAC. Intracavitary pressure gradients were present in 3 of 10 RAS vs. none of TAC or WT. Passive diastolic LV stiffness was not different among the three groups. Myofibrillar disarray was present in all RAS animals and was significantly more extensive (21.7% area fraction) than in TAC (1.5%) or WT (0.0%). RAS mice had selective induction of natriuretic peptide genes in the LV, a pattern distinct from that induced by pressure overload. Juvenile mortality was significantly increased in the offspring of echo-selected RAS parents. We conclude that adaptation of echocardiography to the mouse permits selection for cardiac phenotypes, and that selectively inbred MLC-Ras transgenic mice faithfully reproduce the molecular, physiological, and pathological features of human hypertrophic cardiomyopathy (HCM). Because previous studies support the concept that hypertrophy in human HCM is secondary to dysfunction created by sarcomeric protein mutations, the current studies suggest that Ras-dependent pathways might play a similar role in forms of human HCM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114056      PMCID: PMC20789          DOI: 10.1073/pnas.94.9.4710

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Mid-ventricular obstruction: a variant of obstructive cardiomyopathy.

Authors:  R E Falicov; L Resnekov; S Bharati; M Lev
Journal:  Am J Cardiol       Date:  1976-03-04       Impact factor: 2.778

2.  Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; W C Roberts
Journal:  Circulation       Date:  1979-04       Impact factor: 29.690

3.  Assessment of diastolic function: suggested methods and future considerations.

Authors:  I Mirsky
Journal:  Circulation       Date:  1984-04       Impact factor: 29.690

Review 4.  Hypertrophic cardiomyopathy: subclassification by m mode echocardiography.

Authors:  B W Gilbert; C Pollick; A G Adelman; E D Wigle
Journal:  Am J Cardiol       Date:  1980-04       Impact factor: 2.778

5.  The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis.

Authors:  J Ross; E Braunwald; J H Gault; D T Mason; A G Morrow
Journal:  Circulation       Date:  1966-10       Impact factor: 29.690

6.  Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography.

Authors:  B J Maron; J S Gottdiener; J Arce; D R Rosing; Y E Wesley; S E Epstein
Journal:  J Am Coll Cardiol       Date:  1985-07       Impact factor: 24.094

7.  Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients.

Authors:  B J Maron; J S Gottdiener; S E Epstein
Journal:  Am J Cardiol       Date:  1981-09       Impact factor: 2.778

8.  Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: proposed role in systolic anterior motion of mitral valve.

Authors:  P M Shah; R D Taylor; M Wong
Journal:  Am J Cardiol       Date:  1981-08       Impact factor: 2.778

9.  Expression and distribution of atrial natriuretic peptide in human hypertrophic ventricle of hypertensive hearts and hearts with hypertrophic cardiomyopathy.

Authors:  G Takemura; H Fujiwara; M Mukoyama; Y Saito; K Nakao; A Kawamura; M Ishida; M Kida; T Uegaito; M Tanaka
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

10.  Point mutations in human beta cardiac myosin heavy chain have differential effects on sarcomeric structure and assembly: an ATP binding site change disrupts both thick and thin filaments, whereas hypertrophic cardiomyopathy mutations display normal assembly.

Authors:  K D Becker; K R Gottshall; R Hickey; J C Perriard; K R Chien
Journal:  J Cell Biol       Date:  1997-04-07       Impact factor: 10.539

View more
  15 in total

1.  Cardiomyopathy in Irx4-deficient mice is preceded by abnormal ventricular gene expression.

Authors:  B G Bruneau; Z Z Bao; D Fatkin; J Xavier-Neto; D Georgakopoulos; C T Maguire; C I Berul; D A Kass; M L Kuroski-de Bold; A J de Bold; D A Conner; N Rosenthal; C L Cepko; C E Seidman; J G Seidman
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

2.  Proteomic profiling of H-Ras-G12V induced hypertrophic cardiomyopathy in transgenic mice using comparative LC-MS analysis of thin fresh-frozen tissue sections.

Authors:  Bih-Rong Wei; R Mark Simpson; Donald J Johann; Jennifer E Dwyer; Darue A Prieto; Mia Kumar; Xiaoying Ye; Brian Luke; Heather R Shive; Joshua D Webster; Shelley B Hoover; Timothy D Veenstra; Josip Blonder
Journal:  J Proteome Res       Date:  2012-02-06       Impact factor: 4.466

3.  Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy.

Authors:  C H Redfern; M Y Degtyarev; A T Kwa; N Salomonis; N Cotte; T Nanevicz; N Fidelman; K Desai; K Vranizan; E K Lee; P Coward; N Shah; J A Warrington; G I Fishman; D Bernstein; A J Baker; B R Conklin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 4.  Relevance of mouse models of cardiac fibrosis and hypertrophy in cardiac research.

Authors:  Vikrant Rai; Poonam Sharma; Swati Agrawal; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2016-10-20       Impact factor: 3.396

5.  Network-based predictions of in vivo cardiac hypertrophy.

Authors:  Deborah U Frank; Matthew D Sutcliffe; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2018-07-17       Impact factor: 5.000

6.  Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload.

Authors:  Vera Niederkofler; Rishard Salie; Silvia Arber
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 7.  Genetic analyses of the role of RCE1 in RAS membrane association and transformation.

Authors:  Martin O Bergo; Annika M Wahlstrom; Loren G Fong; Stephen G Young
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

8.  Impact of treatment with melatonin on cerebral circulation in old rats.

Authors:  François Dupuis; Olivier Régrigny; Jeffrey Atkinson; Patrick Limiñana; Philippe Delagrange; Elizabeth Scalbert; Jean-Marc Chillon
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

9.  Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy.

Authors:  R Wessely; K Klingel; L F Santana; N Dalton; M Hongo; W Jonathan Lederer; R Kandolf; K U Knowlton
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

10.  Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy.

Authors:  Manuel Ramos-Kuri; Kleopatra Rapti; Hind Mehel; Shihong Zhang; Perundurai S Dhandapany; Lifan Liang; Alejandro García-Carrancá; Regis Bobe; Rodolphe Fischmeister; Serge Adnot; Djamel Lebeche; Roger J Hajjar; Larissa Lipskaia; Elie R Chemaly
Journal:  Biochim Biophys Acta       Date:  2015-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.